MICHAEL WARD

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -On the creation of an executive branch Office of Caregiver Health -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 3702/H.R. 7165 Credit for Caring Act -National Cholesterol Education Month and LDL-C Awareness Day -FDA Advisory Committee Meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -On the creation of an executive branch Office of Caregiver Health -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -On the creation of an executive branch Office of Caregiver Health -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -On the creation of an executive branch Office of Caregiver Health -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -On the creation of an executive branch Office of Caregiver Health -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 3702/H.R. 7165 Credit for Caring Act -National Cholesterol Education Month and LDL-C Awareness Day -FDA Advisory Committee Meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 3702/H.R. 7165 Credit for Caring Act -National Cholesterol Education Month and LDL-C Awareness Day -FDA Advisory Committee Meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 3702/H.R. 7165 Credit for Caring Act -National Cholesterol Education Month and LDL-C Awareness Day -FDA Advisory Committee Meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 3702/H.R. 7165 Credit for Caring Act -National Cholesterol Education Month and LDL-C Awareness Day -FDA Advisory Committee Meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -On the creation of an executive branch Office of Caregiver Health -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -On the creation of an executive branch Office of Caregiver Health -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform

-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -S. 3109 the Alleviating Barriers for Caregivers Act -Implementation of the Medicare Direct Negotiation Program -Utilization management reform in Medicare -Medicare Advantage Advance Notice of Methodological Changes for Medicare Advantage (MA) Capitation Rates and Part C and D Payment Policies and Draft Calendar Year (CY) 2025 Part D Redesign Instructions

-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -S. 3109 the Alleviating Barriers for Caregivers Act -Implementation of the Medicare Direct Negotiation Program -Utilization management reform in Medicare -Medicare Advantage Advance Notice of Methodological Changes for Medicare Advantage (MA) Capitation Rates and Part C and D Payment Policies and Draft Calendar Year (CY) 2025 Part D Redesign Instructions

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 3702/H.R. 7165 Credit for Caring Act -National Cholesterol Education Month and LDL-C Awareness Day -FDA Advisory Committee Meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 3702/H.R. 7165 Credit for Caring Act -National Cholesterol Education Month and LDL-C Awareness Day -FDA Advisory Committee Meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 3702/H.R. 7165 Credit for Caring Act -National Cholesterol Education Month and LDL-C Awareness Day -FDA Advisory Committee Meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 3702/H.R. 7165 Credit for Caring Act -National Cholesterol Education Month and LDL-C Awareness Day -FDA Advisory Committee Meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee -Pharmacy benefit manager reform

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -National Cholesterol Education Month and LDL-C Awareness Day -CDC on Advisory Committee on Immunizations Practices' four open seats for medical professionals -H.R. 5074 the Kidney PATIENT Act of 2023 -Office of Civil Rights updates to section 504 of the Rehabilitation Act -S. 1001/H.R. 1843 the Telehealth Expansion Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 1339 the Pharmacy Benefit Manager Reform Act -H.R. 6284/S. 3260 the Improving Measurements for Loneliness and Isolation Act

Supported the SALSA Act (H.R. 2377 / S. 1000 to stop Congressional cuts to clinical laboratories

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -National Cholesterol Education Month and LDL-C Awareness Day -CDC on Advisory Committee on Immunizations Practices' four open seats for medical professionals -H.R. 5074 the Kidney PATIENT Act of 2023 -Office of Civil Rights updates to section 504 of the Rehabilitation Act -S. 1001/H.R. 1843 the Telehealth Expansion Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 1339 the Pharmacy Benefit Manager Reform Act -H.R. 6284/S. 3260 the Improving Measurements for Loneliness and Isolation Act

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -FDA on status of safe and effective decongestants -HHS on health disparity populations -Food and Drug Administration's Patient-Focused Drug Development Series

-Increased federal funding for the Neurology Drug Program at the Food and Drug Administration -For H.R. 485 Protecting Health Care for All Patients Act of 2023, in support of a full federal ban on the use of the Quality Adjusted Life Year -Increased federal funding for the Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative in FY 2024 -Increase federal funding for domestic and global antimicrobial resistance programs -Vaccine access

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -National Cholesterol Education Month and LDL-C Awareness Day -CDC on Advisory Committee on Immunizations Practices' four open seats for medical professionals -H.R. 5074 the Kidney PATIENT Act of 2023 -Office of Civil Rights updates to section 504 of the Rehabilitation Act -S. 1001/H.R. 1843 the Telehealth Expansion Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 1339 the Pharmacy Benefit Manager Reform Act -H.R. 6284/S. 3260 the Improving Measurements for Loneliness and Isolation Act

-For H.R. 485 Protecting Health Care for All Patients Act of 2023, in support of a full federal ban on the use of the Quality Adjusted Life Year -Increase federal funding for domestic and global antimicrobial resistance programs -In support of the President's April 18 Executive Order that advances policies that provide resources to family caregivers and advocate for more federal resources to better support them -In support of the United State's Preventative Services Task Force's effort to reevaluate pharmaceutical interventions for obesity

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -National Cholesterol Education Month and LDL-C Awareness Day -CDC on Advisory Committee on Immunizations Practices' four open seats for medical professionals -H.R. 5074 the Kidney PATIENT Act of 2023 -Office of Civil Rights updates to section 504 of the Rehabilitation Act -S. 1001/H.R. 1843 the Telehealth Expansion Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 1339 the Pharmacy Benefit Manager Reform Act -H.R. 6284/S. 3260 the Improving Measurements for Loneliness and Isolation Act

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -National Cholesterol Education Month and LDL-C Awareness Day -CDC on Advisory Committee on Immunizations Practices' four open seats for medical professionals -H.R. 5074 the Kidney PATIENT Act of 2023 -Office of Civil Rights updates to section 504 of the Rehabilitation Act -S. 1001/H.R. 1843 the Telehealth Expansion Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 1339 the Pharmacy Benefit Manager Reform Act -H.R. 6284/S. 3260 the Improving Measurements for Loneliness and Isolation Act

Supported the SALSA Act (H.R. 2377 / S. 1000 to stop Congressional cuts to clinical laboratories

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -National Cholesterol Education Month and LDL-C Awareness Day -CDC on Advisory Committee on Immunizations Practices' four open seats for medical professionals -H.R. 5074 the Kidney PATIENT Act of 2023 -Office of Civil Rights updates to section 504 of the Rehabilitation Act -S. 1001/H.R. 1843 the Telehealth Expansion Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 1339 the Pharmacy Benefit Manager Reform Act -H.R. 6284/S. 3260 the Improving Measurements for Loneliness and Isolation Act

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -National Cholesterol Education Month and LDL-C Awareness Day -CDC on Advisory Committee on Immunizations Practices' four open seats for medical professionals -H.R. 5074 the Kidney PATIENT Act of 2023 -Office of Civil Rights updates to section 504 of the Rehabilitation Act -S. 1001/H.R. 1843 the Telehealth Expansion Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 1339 the Pharmacy Benefit Manager Reform Act -H.R. 6284/S. 3260 the Improving Measurements for Loneliness and Isolation Act

-Lobbied for patient focused approach to the implementation of the Inflation Reduction Act's provisions for an out of pocket cap of $2000 for Medicare beneficiaries and the smoothing of costs for that population -Responded to the Agency's proposed guidance on the direct negotiation provision of the Inflation Reduction Act, advocating for them to avoid using discriminatory metrics like QALYs during the price setting process and asking them to ensure patients were included in those discussions -Responded to an HCPM guidance for implementation of the Part D provisions in the inflation reduction act advocating for patients to have continued access to therapies and for the program to monitor any impacts of direct negotiation on access, as well as recommending best practices for smoothing implementation -Lobbied Congress to have Medicare to create a complimentary measure for their current long-stay antipsychotic measure -Support S. 1544, which directs Medicare to expand access to PET radiopharmaceuticals -Lobbying on Medicare's Alzheimer's disease national coverage determination

-Implementation of Medicare Part D beneficiary affordability provisions -Stakeholder input in the Medicare drug price negotiation process -AP quality measure on antipsychotics for long-term stay in secure nursing facilities -S. 3109 the Alleviating Barriers for Caregivers Act -Implementation of the Medicare Direct Negotiation Program -Implementation of Medicare Prescription Payment Plan -Utilization management reform in Medicare

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -National Cholesterol Education Month and LDL-C Awareness Day -CDC on Advisory Committee on Immunizations Practices' four open seats for medical professionals -H.R. 5074 the Kidney PATIENT Act of 2023 -Office of Civil Rights updates to section 504 of the Rehabilitation Act -S. 1001/H.R. 1843 the Telehealth Expansion Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 1339 the Pharmacy Benefit Manager Reform Act -H.R. 6284/S. 3260 the Improving Measurements for Loneliness and Isolation Act

-H.R. 485 Protecting Health Care for All Patients Act of 2023 -National Cholesterol Education Month and LDL-C Awareness Day -CDC on Advisory Committee on Immunizations Practices' four open seats for medical professionals -H.R. 5074 the Kidney PATIENT Act of 2023 -Office of Civil Rights updates to section 504 of the Rehabilitation Act -S. 1001/H.R. 1843 the Telehealth Expansion Act of 2023 -S. 652/H.R. 2630 the Safe Step Act -S. 1339 the Pharmacy Benefit Manager Reform Act -H.R. 6284/S. 3260 the Improving Measurements for Loneliness and Isolation Act

-FDA continue focus on COVID-19 prevention and treatment options -Patient access to next generation therapeutics to fight COVID-19 -Planning and content of the National Institute on Aging's Research Summit -Support the PASTUER Act (H.R. 3932)

-Held meetings and submitted letters on prescription drug pricing reform recommendations including measures to enhance affordability (Build Back Better, Senate Finance Sec. 129201 and 129202, Innovation Center demonstration projects), limiting out-of-pocket expenses for beneficiaries, moderating annual increases in drug prices, restructuring the cost-sharing, expanding Medicare services to include dental, hearing, and vision, and recommended a federal ban on the quality-adjusted life year (H.R. 5376) -Held meetings with CMS on implementation of a smoothing mechanism for Medicare Part D beneficiaries (H.R. 5376) -CMS end the coverage limit of one lifetime beta amyloid PET scan and provide national coverage for diagnostic evaluation and assessment to start or continue an Alzheimer's therapeutic -Improve Medicare Advantage plans by implementing patient centered utilization and pricing reforms -CMS'proposedrule updating Medicarepaymentand refining policies under the Physician Fee Schedule (PFS) (the Proposed Rule) to include the Fracture Liaison Service (FLS) -Section 139402 (provide first-dollar coverage of adult vaccines recommended by the Advisory Committee on Immunization Practices under Medicare Part D) and Section 139405 (improve access to adult vaccines under Medicaid and CHIP by providing a federal baseline for first-dollar coverage and an enhanced FMAP for immunizing providers.) of the Build Back Better Act. -Revision of CMS quality measure in order to appropriately measure clinically appropriate use of antipsychotic medications in nursing facilities

-Establishing a Neuroscience Center of Excellence within the FDA -H.R. 6000 Cures 2.0 Act

-Establishing a Neuroscience Center of Excellence within the FDA -H.R. 6000 Cures 2.0 Act -FDA clinical trial diversity -Patient-centered outcomes research principles with ARHQ

-Congress to pass S. 4449 / H.R. 8188 the Saving Access to Laboratory Services Act -AHRQ on clinical trial design criteria for Coverage with Evidence Development

-Encourage CDC to ensure patient access to pneumonia vaccines -Support H.R. 9310 The Preventative Services Early Action Act

-Congress to pass S. 4449 / H.R. 8188 the Saving Access to Laboratory Services Act -AHRQ on clinical trial design criteria for Coverage with Evidence Development

Signed a letter in support of the CONNECT for Health Act 2021 (S.1512) Signed a letter in support of the Comprehensive Care for Alzheimers Act (S. 1125/H.R. 2517) Signed a letter from the Medical Imaging and Technology Alliance (MITA) urging the Coverage and Analysis Group within CMS to open the pending reconsideration request for amyloid Positron Emission Tomography (PET) scans. Signed letter urging the House of Representatives and the Senate to create an out-of-pocket cap in Medicare Part D, reform the Part D exceptions and appeals process, bolster the low-income subsidy program, eliminate cost-sharing for Part D vaccines, and improve information and consumer education for Part D beneficiaries. Signed a letter as part of the Psychoactive Appropriate Use for Safety and Effectiveness (Project PAUSE) urging CMS to revise the measures of inappropriate use of antipsychotics in skilled nursing facilities and enhance the documentation to support CMSs ability to assess and investigate inappropriate prescribing practices Submitted letter to Congressional leadership urging an annual out-of-pocket cap in Part D; expansion of low-income subsidy eligibility; placing an inflationary cap in Part D; a requirement that Part D plans share a portion of sales of rebates with beneficiaries at the point of sale; strengthen the Part D appeals process; expand Medicare coverage for dental, vision, and hearing services; and not include the quality-adjusted life year metric in any drug pricing legislation. Sent letter to House of Representatives leadership urging them not to include International Reference Pricing and Quality-Adjust Life Year metrics in drug pricing legislation. Met virtually with the House of Representatives and Senate to discuss creating an annual out-of-pocket cap in Medicare Part D, creating a smoothing proposal, and warning against the use of quality-adjusted life-year metrics to determine drug value.

Held meetings and submitted letters on prescription drug pricing reform recommendations including measures to enhance affordability, limiting out-of-pocket expenses for beneficiaries, moderating annual increases in drug prices, restructuring the cost-sharing, expanding Medicare services to include dental, hearing, and vision, and recommended a federal ban on the quality-adjusted life year. Submitted comments on CMS Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease CAG-00460N Submitted letter CMS-1746-P: Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program and Value-Based Purchasing Program for Federal Fiscal Year 2022 Signed letter on priorities for Telehealth Reform Signed letter on the Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2022 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals Signed letter on the BIOSIM Act (H.R 2815) Signed letter on Request for Information (RFI): Methods and Leading Practices for Advancing Equity and Support for Underserved Communities Through Government Submitted comments on the CY 2022 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule (CMS-1753-P) Submitted comments on the Revisions to Payment Policies under the Medicare Physician Fee Schedule Quality Payment Program and Other Revisions to Part B for CY 2022 (CMS-1751-P)

-Prospective legislation known as 21st Century Cures 2.0 -Cannabis Administration and Opportunity Act (CAOA) Discussion Draft -National paid family and medical leave -Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act (H.R.3354)

-Establishing a Neuroscience Center of Excellence within the FDA -Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S.2706)

Signed Ad Hoc Group for Medical Research letter urging investments in medical research be included in any future legislative package focused on bolstering infrastructure. Further, the letter recommended that Congress pass the RISE Act (H.R. 869/S.289) Signed letter supporting the continued use of human fetal tissue in federal biomedical research

Signed a letter in support of the CONNECT for Health Act 2021 (S.1512) Signed a letter in support of the Comprehensive Care for Alzheimers Act (S. 1125/H.R. 2517) Signed a letter from the Medical Imaging and Technology Alliance (MITA) urging the Coverage and Analysis Group within CMS to open the pending reconsideration request for amyloid Positron Emission Tomography (PET) scans. Signed letter urging the House of Representatives and the Senate to create an out-of-pocket cap in Medicare Part D, reform the Part D exceptions and appeals process, bolster the low-income subsidy program, eliminate cost-sharing for Part D vaccines, and improve information and consumer education for Part D beneficiaries. Signed a letter as part of the Psychoactive Appropriate Use for Safety and Effectiveness (Project PAUSE) urging CMS to revise the measures of inappropriate use of antipsychotics in skilled nursing facilities and enhance the documentation to support CMSs ability to assess and investigate inappropriate prescribing practices Submitted letter to Congressional leadership urging an annual out-of-pocket cap in Part D; expansion of low-income subsidy eligibility; placing an inflationary cap in Part D; a requirement that Part D plans share a portion of sales of rebates with beneficiaries at the point of sale; strengthen the Part D appeals process; expand Medicare coverage for dental, vision, and hearing services; and not include the quality-adjusted life year metric in any drug pricing legislation. Sent letter to House of Representatives leadership urging them not to include International Reference Pricing and Quality-Adjust Life Year metrics in drug pricing legislation. Met virtually with the House of Representatives and Senate to discuss creating an annual out-of-pocket cap in Medicare Part D, creating a smoothing proposal, and warning against the use of quality-adjusted life-year metrics to determine drug value.

Signed a letter in support of the CONNECT for Health Act 2021 (S.1512) Signed a letter in support of the Comprehensive Care for Alzheimers Act (S. 1125/H.R. 2517) Signed a letter from the Medical Imaging and Technology Alliance (MITA) urging the Coverage and Analysis Group within CMS to open the pending reconsideration request for amyloid Positron Emission Tomography (PET) scans. Signed letter urging the House of Representatives and the Senate to create an out-of-pocket cap in Medicare Part D, reform the Part D exceptions and appeals process, bolster the low-income subsidy program, eliminate cost-sharing for Part D vaccines, and improve information and consumer education for Part D beneficiaries. Signed a letter as part of the Psychoactive Appropriate Use for Safety and Effectiveness (Project PAUSE) urging CMS to revise the measures of inappropriate use of antipsychotics in skilled nursing facilities and enhance the documentation to support CMSs ability to assess and investigate inappropriate prescribing practices Submitted letter to Congressional leadership urging an annual out-of-pocket cap in Part D; expansion of low-income subsidy eligibility; placing an inflationary cap in Part D; a requirement that Part D plans share a portion of sales of rebates with beneficiaries at the point of sale; strengthen the Part D appeals process; expand Medicare coverage for dental, vision, and hearing services; and not include the quality-adjusted life year metric in any drug pricing legislation. Sent letter to House of Representatives leadership urging them not to include International Reference Pricing and Quality-Adjust Life Year metrics in drug pricing legislation. Met virtually with the House of Representatives and Senate to discuss creating an annual out-of-pocket cap in Medicare Part D, creating a smoothing proposal, and warning against the use of quality-adjusted life-year metrics to determine drug value.

-Establishing a Neuroscience Center of Excellence within the FDA -Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S.2706)

Signed Ad Hoc Group for Medical Research letter urging investments in medical research be included in any future legislative package focused on bolstering infrastructure. Further, the letter recommended that Congress pass the RISE Act (H.R. 869/S.289) Signed letter supporting the continued use of human fetal tissue in federal biomedical research

Signed a Protecting Access to Pain Relief (PAPR) Coalition letter urging HHS to explore and support new efforts and support new efforts to promote the work and recommendations of the HHS Pain Management Best Practices Inter-Agency Task Force. Signed letter in support of H.R. 8920, the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act

-Signed letter a letter from Justice in Aging on general principles for COVID-19 health emergency legislation The letter called to make racial equity an affirmative goal of all recovery programs, the collection of robust intersectional data on populations impacted by COVID-19; expansion of stimulus payments, increases in the SSI benefit; a suspension or raise to the asset limits for means tested programs including SSI, Medicaid, Medicare Savings Programs, Medicare Low Income subsidies, SNAP, LIHEAP, and other means tested program; extension of paid leave to all family caregivers; expansion of HCBS and Medicare Savings Programs; Increases to the FMAP; Expanded Medicare enrollment periods; Suspension of Medicare premiums for persons below 200 of the federal poverty line; require transparency about infections and staffing levels in nursing facilities and other licensed congregate settings; funding for the Access Act (S. 3517/H.R. 6487); ensure that language interpretation services are available for community-based organizations; ensure all caregivers and aging network services providers have adequate personal protective equipment; expand housing and protection supports, including section 202 supportive housing for seniors and energy assistance to HUD. -Signed letter requesting Congress require the CDC to update the COVID-19 surveillance systems to collect data on patients race, ethnicity, sex, age, primary language, sexual orientation, disability status, gender identity, and socioeconomic status in line with federal standards, and as a threshold, comport with the standards codified by Section 4302 of the Affordable Care Act. -Signed letter from the Consortium for Citizens with Disabilities (CCD) to write about concerns over a deadline for Society Security beneficiaries to file taxes or utilize a web tool claim economic impact payments for child dependents under the age of 17 or wait until 2021 to claim the payments. -Submitted a letter to CMS and the Office of Civil Rights asking they develop and release detailed guidance on how medical resources are being fairly allocated during the COVID-19 pandemic. -Signed a letter urging the FDA and NIH to consider factors that require individualization of treatment for pain, including genetic, sex, and age differences as they implement the SUPPORT Act. The letter asked NIH to implement section 7042 of the SUPPORT Act a priority to help clinicians and researchers individualize treatment plans and options.

Meeting with Senate Finance Committee staff to discuss recommendations for xx Signed letter asking requesting that all health education materials related to COVID-19 be accessible in at least 19 written languages and American Sign Language, support for interpretation services at COVID-19 testing sites, and to make comprehensive data available through the collection of regular reporting of language and disability characteristic of COVID-19 cases The Alliance for Aging Research publicly supported S.Res.655 - A resolution declaring racism a public health crisis. Signed a letter to House Telehealth Caucus in support of Protecting Access to Post-COVID-19 Telehealth Act of 2020 (HR 7663). Signed a letter requesting $10 million for the Administration on Community Living and $4 million for the Centers for Disease Control and Prevention to increase support for falls prevention. Had a meeting with Senate Finance staff to discuss the Committee's priorities to improve the treatment and care coordination for Alzheimer's disease patients after its hearing entitled "Alzheimers Awareness: Barriers to Diagnosis, Treatment, and Care Coordination" Signed letter requesting Congress address the need to expand access to COVID-19 and influenza testing and immunization by designating pharmacists as providers under Medicare Part B.

-Signed letter a letter from Justice in Aging on general principles for COVID-19 health emergency legislation The letter called to make racial equity an affirmative goal of all recovery programs, the collection of robust intersectional data on populations impacted by COVID-19; expansion of stimulus payments, increases in the SSI benefit; a suspension or raise to the asset limits for means tested programs including SSI, Medicaid, Medicare Savings Programs, Medicare Low Income subsidies, SNAP, LIHEAP, and other means tested program; extension of paid leave to all family caregivers; expansion of HCBS and Medicare Savings Programs; Increases to the FMAP; Expanded Medicare enrollment periods; Suspension of Medicare premiums for persons below 200 of the federal poverty line; require transparency about infections and staffing levels in nursing facilities and other licensed congregate settings; funding for the Access Act (S. 3517/H.R. 6487); ensure that language interpretation services are available for community-based organizations; ensure all caregivers and aging network services providers have adequate personal protective equipment; expand housing and protection supports, including section 202 supportive housing for seniors and energy assistance to HUD. -Signed letter requesting Congress require the CDC to update the COVID-19 surveillance systems to collect data on patients race, ethnicity, sex, age, primary language, sexual orientation, disability status, gender identity, and socioeconomic status in line with federal standards, and as a threshold, comport with the standards codified by Section 4302 of the Affordable Care Act. -Signed letter from the Consortium for Citizens with Disabilities (CCD) to write about concerns over a deadline for Society Security beneficiaries to file taxes or utilize a web tool claim economic impact payments for child dependents under the age of 17 or wait until 2021 to claim the payments. -Submitted a letter to CMS and the Office of Civil Rights asking they develop and release detailed guidance on how medical resources are being fairly allocated during the COVID-19 pandemic. -Signed a letter urging the FDA and NIH to consider factors that require individualization of treatment for pain, including genetic, sex, and age differences as they implement the SUPPORT Act. The letter asked NIH to implement section 7042 of the SUPPORT Act a priority to help clinicians and researchers individualize treatment plans and options.

Meeting with Senate Finance Committee staff to discuss recommendations for xx Signed letter asking requesting that all health education materials related to COVID-19 be accessible in at least 19 written languages and American Sign Language, support for interpretation services at COVID-19 testing sites, and to make comprehensive data available through the collection of regular reporting of language and disability characteristic of COVID-19 cases The Alliance for Aging Research publicly supported S.Res.655 - A resolution declaring racism a public health crisis. Signed a letter to House Telehealth Caucus in support of Protecting Access to Post-COVID-19 Telehealth Act of 2020 (HR 7663). Signed a letter requesting $10 million for the Administration on Community Living and $4 million for the Centers for Disease Control and Prevention to increase support for falls prevention. Had a meeting with Senate Finance staff to discuss the Committee's priorities to improve the treatment and care coordination for Alzheimer's disease patients after its hearing entitled "Alzheimers Awareness: Barriers to Diagnosis, Treatment, and Care Coordination" Signed letter requesting Congress address the need to expand access to COVID-19 and influenza testing and immunization by designating pharmacists as providers under Medicare Part B.